Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Status: SUSPENDED
Study type: INTERVENTIONAL
Conditions: Breast Adenocarcinoma|Metastatic Breast Carcinoma|Recurrent Breast Carcinoma|Recurrent Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Breast Carcinoma|Refractory Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Nodal Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Breast Cancer AJCC v6 and v7
Interventions: DRUG: Belinostat|DRUG: Carfilzomib|DRUG: Copanlisib Hydrochloride|BIOLOGICAL: Daratumumab|DRUG: Fludeoxyglucose F-18|DRUG: Gemcitabine Hydrochloride|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab|BIOLOGICAL: Obinutuzumab|BIOLOGICAL: Pembrolizumab|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Rituximab|DRUG: Romidepsin|OTHER: Saline|BIOLOGICAL: Trastuzumab
Sponsor: Mayo Clinic